EarlySight is thrilled to announce the appointment of Jérôme Martinez as an independent board member. With his deep expertise and proven leadership in the pharmaceutical, biotechnology, and medical device sectors, Jérôme will play a pivotal role in helping EarlySight navigate its next phase of growth and development. He will lend his insight to advance Early Sight’s groundbreaking cellular level imaging technology, working to make it a routine diagnostic tool in modern healthcare.
Jérôme Martinez brings over 30 years of international experience, currently serving on the boards of MDoloris, Theranexus, and ErVimmune. His extensive track record includes leadership roles at major healthcare companies. As for Ophthalmology, he led the French operations of SANTEN, a Japanese pharmaceutical company specializing in ophthalmology and rheumatology, from 2012 to 2017. Notably, Jérôme was Chairman of the Executive Board at Novagali Pharma from 2004 to 2011, where he successfully managed its IPO and subsequent acquisition by SANTEN. Under his leadership, Novagali Pharma secured the first European marketing authorization for an ophthalmic cyclosporine treatment.
Jérôme holds a Doctor of Pharmacy degree, a Master’s in Health Administration Law from the University of Paris XI, and an MBA from both HEC Paris and Keio Business School in Tokyo. He has further sharpened his business acumen through executive programs at Northwestern University’s JL Kellogg Graduate School of Management and at INSEAD where he got a Certificate in Corporate Governance attending the International Director Program.
We are confident that Jérôme’s wealth of experience and strategic vision will be instrumental in propelling EarlySight towards its mission of revolutionizing retinal imaging.
